Top-Ten Pharmaceutical Organization Selects Cardiocore as Preferred Provider
Washington, DC – 10.August.2009 – Cardiocore, a premier centralized cardiac testing lab, announced today that it has been selected as a preferred provider by another Top-Ten pharmaceutical company. As part of its selection process, this drug developer analyzed detailed information from the leading core labs in the United States and Europe. Factors contributing to Cardiocore’s selection included its flexible data management systems, world class scientists and highly-qualified project management organization.
|
||
| About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 16 years. Services include centralized electrocardiography (ECG), Holter, echocardiography (ECHO), multigated acquisition scans (MUGA), and consulting services such as protocol development, scientific reporting and statistical analyses. The company is experienced in the design and the implementation of cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company’s advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com | ||
Download as a PDF file. |
